Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also di...
| Autores principales: | , , , |
|---|---|
| Formato: | info:ar-repo/semantics/artículo |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.sciencedirect.com/science/article/pii/S0264410X19310230 http://hdl.handle.net/20.500.12123/6312 https://doi.org/10.1016/j.vaccine.2019.07.102 |
| _version_ | 1855035653216010240 |
|---|---|
| author | Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. |
| author_browse | Capozzo, Alejandra Victoria Ludi, A. Paton, D. J. Reeve, R. |
| author_facet | Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. |
| author_sort | Paton, D. J. |
| collection | INTA Digital |
| description | Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements. |
| format | info:ar-repo/semantics/artículo |
| id | INTA6312 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2019 |
| publishDateRange | 2019 |
| publishDateSort | 2019 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | INTA63122019-11-07T17:51:40Z Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements. Instituto de Virología Fil: Paton, D. J. The Pirbright Institute; Reino Unido Fil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino Unido Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ludi, A. The Pirbright Institute; Reino Unido 2019-11-07T17:43:18Z 2019-11-07T17:43:18Z 2019-09 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://www.sciencedirect.com/science/article/pii/S0264410X19310230 http://hdl.handle.net/20.500.12123/6312 0264-410X https://doi.org/10.1016/j.vaccine.2019.07.102 eng info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Vaccine 37 (37) : 5515-5524. (3 September 2019) |
| spellingShingle | Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title | Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title_full | Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title_fullStr | Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title_full_unstemmed | Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title_short | Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
| title_sort | estimating the protection afforded by foot and mouth disease vaccines in the laboratory |
| topic | Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection |
| url | https://www.sciencedirect.com/science/article/pii/S0264410X19310230 http://hdl.handle.net/20.500.12123/6312 https://doi.org/10.1016/j.vaccine.2019.07.102 |
| work_keys_str_mv | AT patondj estimatingtheprotectionaffordedbyfootandmouthdiseasevaccinesinthelaboratory AT reever estimatingtheprotectionaffordedbyfootandmouthdiseasevaccinesinthelaboratory AT capozzoalejandravictoria estimatingtheprotectionaffordedbyfootandmouthdiseasevaccinesinthelaboratory AT ludia estimatingtheprotectionaffordedbyfootandmouthdiseasevaccinesinthelaboratory |